Merck's Oral PCSK9 Inhibitor Gets a Manufacturing Boost, but Pipeline Impact Remains Distant

What happened

Merck scientists published a landmark paper in Science detailing a novel biocatalytic method for large-scale synthesis of enlicitide decanoate, its investigational oral PCSK9 inhibitor. While this is a scientific achievement that could enable oral macrocyclic peptide drugs, enlicitide is still in development and its commercial contribution is years away. For a company contending with a ~$2.5B 2026 headwind, Gardasil-China uncertainty, and the looming Keytruda patent cliff, this news does not alter the near-term financial trajectory. The paper adds a positive pipeline datapoint but does not change the fundamental earnings bridge for 2026-2027.

Implication

The publication validates Merck's ability to tackle complex oral peptide synthesis, which could expand its future pipeline optionality. However, given the company's current challenges—Keytruda LOE, Gardasil China pause, and patent expiries—investors should not overreact. The stock remains a WAIT with an attractive entry near $105; this news alone does not warrant a rating change.

Thesis delta

This milestone adds a positive data point to Merck's pipeline progression, supporting the narrative that the company is building post-Keytruda pillars through internal R&D alongside M&A. However, the immediate thesis remains unchanged: 2026 performance hinges on containment of the ~$2.5B headwind and visibility on Gardasil-China restart. The paper does not alter the 6-12 month outlook or the WAIT rating.